Ser206
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser206  -  Claudin-7 (human)

Site Information
RsYPksNsskEyV__   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 486329

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 4 ) , mutation of modification site ( 3 ) , western blotting ( 3 )
Disease tissue studied:
breast cancer ( 1 ) , breast ductal carcinoma ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 2 , 3 , 4 ) , non-small cell lung cancer ( 3 , 4 ) , non-small cell lung adenocarcinoma ( 2 ) , ovarian cancer ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Kinases, in vitro:
WNK4 (human) ( 5 )
Treatments:
ischemia ( 1 )

References 

1

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

2

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

3

Hoggard J, et al. (2013) Claudin-7 increases chemosensitivity to cisplatin through the upregulation of caspase pathway in human NCI-H522 lung cancer cells. Cancer Sci 104, 611-8
23433123   Curated Info

4

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

5

Tatum R, et al. (2007) WNK4 phosphorylates ser(206) of claudin-7 and promotes paracellular Cl(-) permeability. FEBS Lett 581, 3887-91
17651736   Curated Info